Infectious Disease Treatment Market in China 2016-2020

Table of Contents

PART 01: Executive summary

• Highlights

PART 02: Scope of  the report

• Market overview
• Assumptions
• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights

PART 05: China - An overview

• Social and economic conditions
• Healthcare reforms
• Healthcare infrastructure

PART 06: Opportunities for global and local vendors

• Local vendors
• Global vendors

PART 07: Pipeline analysis

• AC-170
• DEXTENZA
• Zerbaxa
• Surotomycin
• MK-3415A
• Amikacin Inhale
• CARBAVANCE
• Eravacycline
• Plazomicin
• Delafloxacin
• Solithromycin
• VivaGel
• Arikayce
• Cadazolid
• Ozenoxacin
• TDT 067
• MOB-015
• 1334H
• Auriclosene
• EBI-005
• FST-100
• VT-1161
• Luliconazole solution, 10%
• ME1111
• NP213
• HXP124
• SPL7013
• OPX-1
• AzaSite Xtra (ISV-405)
• GD134
• PART 08: Market landscape
• Pharmaceutical market in China
• Market overview
• Market size and forecast
• Five forces analysis

PART 09: Market segmentation  by application

PART 10: Antibacterial drugs market in China

• MOA
• Market size and forecast

PART 11: Antiviral drugs market in China

• Market size and forecast
• Market segmentation by disease
• Hepatitis C drugs market in China
• Hepatitis B drugs market in China
• HIV drugs market in China

PART 12: Antifungal drugs market in China

• Market size and forecast

PART 13: Antiparasitic drugs market in China

PART 14: Market drivers

• Climatic changes
• Increased exposure to chemicals and pollutants
• Use of combination therapies
• Increased prevalence of infectious diseases
• Increase in awareness

PART 15: Impact of drivers

PART 16: Market challenges

• Counterfeit drugs
• Development of drug-resistant strains
• Patent expiries and generic penetration
• Decreased investments in research
• Increased use of generics and CAMs

PART 17: Impact of drivers and challenges

PART 18: Market trends

• Increase in collaborations and M&A
• Emergence of IFN-free therapies
• Increase in injection drug users

PART 19: Vendor landscape

• Competitive scenario
• F. Hoffmann-La Roche
• Gilead Sciences
• GSK
• Johnson & Johnson
• Merck
• Pfizer
• Other prominent vendors

PART 20: Appendix

• List of abbreviations

PART 21: Explore Technavio